首頁 > 市場調查報告書 > 製藥

非專利藥

市場調查報告書

商品編碼

2024585

學名藥市場報告：按治療領域、給藥途徑、分銷管道和國家/地區分類（2026-2034 年）

Generic Drugs Market Report by Therapy Area, Drug Delivery, Distribution Channel, and Country 2026-2034

出版日期: 2026年04月01日 | 出版商:

IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025年，全球學名藥市場規模達4,110億美元。展望未來，IMARC Group預測，2026年至2034年間，該市場將以5.60%的複合年成長率成長，到2034年達到6,814億美元。截至2025年，美國憑藉大型製藥企業的強大實力和製劑創新，在該市場佔據主導地位。慢性病盛行率的上升和專利到期是推動該市場成長的主要因素。政府旨在降低醫療成本的支援政策也促進了學名藥市場佔有率的成長。

市場規模及預測：

預計到 2025 年，學名藥市場規模將達到 4,110 億美元。
預計到 2034 年，市場規模將達到 6,814 億美元，2026 年至 2034 年的複合年成長率為 5.60%。

主要部分：

治療領域：中樞神經系統疾病是推動學名藥市場發展的主要因素。這是因為憂鬱症、癲癇、帕金森氏症和焦慮症等中樞神經系統疾病具有慢性、廣泛性等特點，且需要長期用藥。學名藥提供了一種經濟有效的治療選擇，能夠改善這些終身神經系統疾病患者的治療可近性和用藥依從性。
藥物遞送：口服給藥佔市場主導地位。這是因為它是最便捷、非侵入性且患者更傾向選擇的給藥途徑。片劑和膠囊易於生產、儲存和運輸，使其成為學名藥大規模分銷的理想選擇。
通路：零售藥局佔據最大的市場佔有率，因為它們是人們購買藥品最方便的場所。憑藉其廣泛的門市網路和與患者的直接接觸，零售藥局正在推動學名藥銷售的成長，尤其是在常用處方箋。
國家：美國憑藉其高度發展的藥品生產基礎設施、龐大的處方箋量以及藥房對學名藥的早期接受度，在市場上佔據領先地位。具有競爭力的價格以及眾多學名藥專家的存在，進一步鞏固了美國在全球學名藥市場的主導地位。

主要公司：

學名藥市場的主要參與者包括梯瓦製藥工業公司、邁蘭製藥公司、諾華製藥公司、輝瑞製藥公司、太陽製藥工業公司、費森尤斯製藥公司、魯賓製藥公司、恩多製藥公司、奧羅賓多製藥公司和阿斯彭製藥控股公司。

市場成長的主要促進因素：

人口老化：老年人面臨需要長期服藥的慢性疾病。學名藥價格實惠，對於收入固定的老年患者來說至關重要。隨著老年人口的成長，對經濟有效的治療方法的需求也日益增加，這促使醫療系統採用學名藥以增強經濟永續性。
線上藥局的擴張：線上藥局透過提供宅配服務、電子處方箋和便利的價格比較功能，提高了人們獲取學名藥的便利性。它們幫助人們，尤其是偏遠地區的居民，方便地找到經濟實惠的替代藥物。隨著線上平台的擴張，學名藥在不同患者群體中的認知度、可及性和銷售量都在不斷提升。
生物等效性核准數量增加：生物等效性核准數量的增加確保了學名藥符合安全性和有效性的監管標準。這增強了醫療專業人員和患者的信心，並促進了學名藥的更廣泛應用。
劑型創新：緩釋片和掩味糖漿等創新劑型提高了病患的依從性和用藥便利性。這些改進使學名藥對不同年齡層和具有不同醫療保健需求的人更具吸引力。
擴大公共和私人醫療保險的覆蓋範圍：擴大醫療保險的覆蓋範圍可以提高藥品的可及性，同時降低成本。保險公司通常更傾向於使用學名藥，因為學名藥價格更低，而且保險公司會透過報銷政策來促進學名藥的使用。

未來展望：

強勁成長前景：受專利到期、消費者對價格合理藥品的需求不斷成長以及全球醫療服務可及性提高的推動，學名藥市場預計將持續擴張。在製藥生產創新、持續關注成本控制以及不斷成長的治療需求的支撐下，該市場預計將穩步成長。
市場演變：預計該領域將從利基市場轉變為全球醫療保健體系的主流組成部分。監管支援、生產流程改進和市場接受度提高正在推動市場成長。它在擴大全球基本藥物的可及性方面發揮著至關重要的作用。

控制醫療成本的日益成長是推動這一市場發展的因素。這促使人們選擇使用學名藥而非品牌藥以降低醫療支出。重磅藥物專利到期也為非專利藥生產商提供了向市場推出價格更親民的替代藥物的機會。此外，政府透過宣傳活動和強制性替代政策來推廣學名藥的使用，也刺激了市場需求。醫療基礎設施的擴建也加速了學名藥的普及。許多地區的監管改革和簡化的核准流程使企業能夠更方便、更快速地將學名藥推向市場。本地和國際製藥公司之間日益增多的合作進一步增強了生產能力和分銷網路。消費者，尤其是中低收入地區的消費者，對價格的敏感度也推動了對價格實惠藥品的需求。

學名藥市場趨勢：

人口老化的過程

人口老化對市場產生了正面影響。老年人通常更容易患上慢性病和與老齡化相關的疾病，例如關節炎、糖尿病、聽力下降、心血管疾病和神經系統疾病。世界衛生組織（世衛組織）預測，到2030年，全球六分之一的人口將超過60歲。隨著老齡化通常需要長期服藥，而學名藥為持續治療提供了一種經濟有效的解決方案。此外，對於收入有限且固定的退休人員來說，經濟實惠的藥物選擇至關重要。隨著各國政府努力控制醫療保健成本，學名藥正成為老年人國家醫療保險計劃中的首選。

網路藥局的擴張

線上藥局的擴張正在推動學名藥的可及性和可負擔性。根據IMARC Group預測，到2024年，全球線上藥局市場規模將達到1,077億美元。線上平台使患者能夠更輕鬆地比較價格、找到更便宜的學名藥，並無需前往實體藥房即可獲得藥品。這對於居住在偏遠地區或行動不便的人來說尤其有利。線上藥局經常提供學名藥的促銷和折扣，使其成為注重成本的消費者更具吸引力的選擇。此外，數位化模式支持處方箋驗證、定期更新處方箋和送貨上門，簡化了學名藥長期治療的管理流程。透過提供更廣泛的藥品選擇和更透明的藥品定價，線上藥局正在推動學名藥的普及。隨著線上醫療平台的不斷發展，預計其對學名藥銷售的貢獻將穩步成長。

擴大治療區域

腫瘤等治療領域的拓展正在推動市場成長。隨著品牌腫瘤藥物專利的到期，學名藥以更低的價格上市，擴大了患者的用藥範圍，並減輕了醫療系統的經濟負擔。隨著癌症發生率的上升，對價格合理的治療方法的需求持續激增，促使製藥商開發並推出更多學名藥。根據美國國立衛生研究院 (NIH) 預測，到 2024 年，美國將新增 2,001,140 例癌症病例。此外，腫瘤聯合治療的日益普及也催生了對多種學名藥的需求。醫院和治療中心傾向於選擇學名藥來控制成本，同時又不影響病人的治療效果。醫療服務提供者對具成本效益替代方案的倡導進一步推動了這一趨勢，強化了學名藥在各個治療領域的作用。

學名藥市場的主要成長要素：

生物等效核准增加

生物等效性核准數量的不斷增加，正在加速品牌藥的低成本替代品進入市場。生物等效性認證確保學名藥與品牌藥具有相同的活性成分、劑型和治療效果，並符合安全性和有效性的監管標準。隨著越來越多的學名藥獲得美國食品藥物管理局（FDA）等機構的核准，生產商可以更有信心地生產和銷售這些藥物，從而減少競爭並降低價格。這增強了大眾對學名藥的信心，並促進了醫療專業人員對學名藥的採用。此外，核准流程的簡化也減少了非專利藥生產商的研發時間和成本。總而言之，生物等效性核准的增加正在擴大學名藥的供應範圍，並有助於減輕患者和醫療保健系統的經濟負擔。

藥物創新

製劑創新正在提升藥物穩定性、病患依從性和治療效果。改進的給藥方式，例如緩釋片、口腔崩壞片和掩味糖漿，使學名藥更易於獲取，並適用於更廣泛的患者群體。這些進步使非專利生產商能夠在提供價格實惠的選擇的同時，實現產品差異化。此外，固定劑量組合藥物的創新提高了用藥便利性，尤其對患有多種慢性疾病的患者而言。新的劑型也有助於提高患者依從性，從而減少治療失敗和再入院，這在以價值為導向的醫療保健系統中至關重要。這些創新使學名藥超越了簡單的仿製品，吸引了處方醫生和消費者的更多關注。在日益激烈的競爭中，各公司正投資研發更優質的學名藥，在維持成本效益的同時，提升其吸引力和療效。

擴大公共和私人醫療保險的覆蓋範圍

公共和私人醫療保險覆蓋範圍的擴大是推動市場發展的主要因素之一，因為保險公司通常會在不影響患者照護的前提下優先考慮降低成本。由於學名藥在大規模藥品報銷中提供了一種經濟可行的解決方案，因此在保險處方藥清單中更受青睞。隨著覆蓋範圍的擴大，更多人將能夠獲得基本藥物，保險公司也將能夠通過基於用量的契約，在學名藥價格談判中獲得有利條件。此外，醫療保險系統通常包含獎勵和義務機制，鼓勵在有學名藥可用時使用，從而進一步促進學名藥的普及。隨著已開發地區和發展中地區保險覆蓋範圍的擴大，對價格合理的學名藥的需求也在不斷成長。這一趨勢推動了學名藥生產和分銷的穩定成長，幫助醫療系統在確保患者透過保險獲得所需藥物的同時，更好地管理預算。

市場結構
Market Breakup：by Key Players
Key Player Profiles
- Teva Pharmaceuticals Industries Ltd.
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Fresenius SE & Co.
- Lupin Limited
- Endo Pharmaceuticals Inc.
- Aurobindo Pharma Limited
- Aspen Pharmacare Holdings Limited

第11章：學名藥生產流程

第12章：項目詳情、需求及相關成本

第13章貸款與財務支持

第14章專案經濟學

簡介目錄

Product Code: SR112026A549

The global generic drugs market size reached USD 411.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 681.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.60% during 2026-2034. United States dominates the market in 2025, driven by the strong presence of major pharmaceutical firms and innovations in formulations. The market is driven by the increasing incidence of chronic diseases, and expiring drug patents. Supportive government policies aimed at reducing healthcare spending are fueling the generic drugs market share.

MARKET SIZE & FORECASTS:

Generic drugs market was valued at USD 411.0 Billion in 2025.
The market is projected to reach USD 681.4 Billion by 2034, at a CAGR of 5.60% from 2026-2034.

DOMINANT SEGMENTS:

Therapy Area: Central nervous system leads the generic drugs market because central nervous system disorders, such as depression, epilepsy, Parkinson's, and anxiety, are chronic and widespread, requiring long-term medication. Generic drugs offer cost-effective treatment options, increasing accessibility and adherence for patients dealing with these lifelong neurological conditions.
Drug Delivery: Oral dominates the market since it is the most convenient, non-invasive, and patient-preferred route. Tablets and capsules are easy to produce, store, and transport, making them ideal for mass distribution of generics.
Distribution Channel: Retail pharmacies represent the largest market share as they are the most accessible point of purchase for people. With widespread presence and direct interaction with patients, retail pharmacies aid in driving higher volume sales of generics, especially for recurring prescriptions.
Country: United States leads the market due to a well-developed pharmaceutical manufacturing base, high prescription volumes, and early adoption of generic substitution by pharmacies. Competitive pricing and the presence of numerous generic-focused companies are further contributing to the country's leadership in the global generic drugs landscape.

KEY PLAYERS:

The leading companies in generic drugs market include Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, etc.

KEY DRIVERS OF MARKET GROWTH:

Rising Aging Population: The elderly population is facing chronic illnesses requiring long-term medication. Generic drugs offer affordable options, making them essential for elderly patients on fixed incomes. As the senior population is growing, the demand for cost-effective treatments is rising, encouraging healthcare systems to employ generic drugs for better economic sustainability.
Broadening of E-pharmacies: E-pharmacies improve access to generic drugs by offering home delivery, digital prescriptions, and easy price comparisons. They help people find cost-effective alternatives conveniently, especially in remote areas. As online platforms are expanding, they are driving greater awareness, availability, and sales of generic drugs across diverse patient populations.
Increased Bioequivalence Approvals: Rising bioequivalence approvals ensure that generics meet regulatory standards for safety and efficacy. This aids in building trust among healthcare providers and patients, encouraging broader adoption of generic drugs.
Innovations in Formulations: Innovative formulations like extended-release tablets and taste-masked syrups enhance patient compliance and convenience. These improvements make generic drugs more appealing to diverse age groups and medical needs.
Expansion of Public and Private Health Insurance Coverage: Broader health insurance coverage increases access to medications while controlling costs. Insurers often favor generic drugs for their affordability, encouraging widespread use through reimbursement policies.

FUTURE OUTLOOK:

Strong Growth Outlook: The generic drugs market is anticipated to see sustained expansion, driven by patent expirations, rising demand for affordable medications, and increasing healthcare access globally. With continued focus on cost containment and expanding therapeutic needs, the market is set to grow steadily, supported by innovations in drug manufacturing.
Market Evolution: The sector is anticipated to shift from a niche segment to a mainstream component of global healthcare systems. The market is advancing through regulatory support, improved manufacturing practices, and greater acceptance. It is playing a key role in increasing access to essential medicines worldwide.

The market is driven by the growing focus on cost containment in healthcare systems, which is encouraging the use of generic drugs over branded medicines to reduce expenditure. Patent expirations of blockbuster drugs also open opportunities for generic manufacturers to introduce affordable alternatives. Additionally, government initiatives aimed at promoting the utilization of generic drugs through awareness programs and mandatory substitution policies are catalyzing the demand. Moreover, expanding healthcare infrastructure is facilitating the penetration of generic medications. Regulatory reforms and streamlined approval processes in many regions have made it easier and faster for companies to bring generic drugs to the market. Increasing partnerships between local and international pharmaceutical firms are further enhancing production capacity and distribution networks. Price sensitivity among users, especially in low- and middle-income regions, is also driving the demand for affordable drug options.

GENERIC DRUGS MARKET TRENDS:

Rising aging population

The growing aging population is positively influencing the market, as older adults generally experience a higher prevalence of chronic and age-related conditions, such as arthritis, diabetes, hearing loss, cardiovascular diseases, and neurological disorders. As per the World Health Organization (WHO), by 2030, one in every six people worldwide will be aged 60 or above. With increasing age, individuals typically require long-term medication, and generic drugs offer a cost-effective solution for sustained treatment. Moreover, pensioners and retirees often rely on limited fixed incomes, making economical drug options essential. As government agencies are seeking to manage public healthcare spending, generic drugs are becoming a preferred choice in national health plans targeting senior citizens.

Expansion of e-pharmacies

The expansion of e-pharmacies is enhancing the accessibility and affordability of generic drugs. As per the IMARC Group, the global e-pharmacy market size was valued at USD 107.70 Billion in 2024. Online platforms make it easier for patients to compare prices, discover lower-cost generic alternatives, and access medications without visiting a physical pharmacy. This is especially beneficial for individuals in remote areas or with limited mobility. E-pharmacies often run targeted promotions and discounts on generic drugs, making them more attractive to cost-conscious buyers. Additionally, the digital model supports prescription verification, subscription refills, and home delivery, streamlining the process of managing long-term therapies using generic medications. By offering a wider range of options and greater transparency in drug pricing, e-pharmacies are enabling higher adoption of generic drugs. As online healthcare platforms continue to expand, their contribution to generic drug sales is expected to grow steadily.

Growth of therapeutic areas

The growth of therapeutic areas, such as oncology, is impelling the market growth. As patents for branded oncology drugs expire, generic versions become available at much lower costs, enabling broader access for patients and easing the financial burden on healthcare systems. With rising cancer prevalence, the demand for affordable therapies continues to surge, leading manufacturers to develop and launch more oncology generics. As per the NIH, in 2024, it was anticipated that there would be 2,001,140 new cancer cases in the United States. Additionally, the increased use of combination therapies in oncology is creating the need for multiple generic drugs. Hospitals and treatment centers prefer generic drugs to manage expenditure without compromising patient outcomes. This trend is further supported by healthcare providers advocating cost-efficient alternatives, reinforcing the role of generic drugs in therapeutic areas.

KEY GROWTH DRIVERS OF GENERIC DRUGS MARKET:

Increased bioequivalence approvals

Increased bioequivalence approvals are facilitating faster market entry of cost-effective alternatives to branded medicines. Bioequivalence ensures that a generic drug has the same active ingredients, dosage form, and therapeutic effects as its branded counterpart, meeting regulatory standards for safety and efficacy. As more generics receive these approvals from authorities, such as the US Food and Drug Administration (FDA), manufacturers can produce and distribute them with confidence, leading to greater competition and price reductions. This also enhances public trust in generic drugs and encourages wider adoption by healthcare providers. Additionally, streamlined approval processes reduce development timelines and costs for generic manufacturers. Overall, increased bioequivalence approvals are contributing to broadening the availability of generic drugs and improving affordability for patients and healthcare systems alike.

Innovations in formulations

Innovations in formulations are refining drug stability, patient compliance, and therapeutic outcomes. Enhanced drug delivery methods, such as extended-release tablets, orally disintegrating forms, and taste-masked syrups, make generics more user-friendly and adaptable across different patient groups. These advancements allow generic manufacturers to differentiate their products while offering them at affordable prices. Additionally, innovation in fixed-dose combinations increases convenience, especially for patients managing multiple chronic conditions. Novel formulations also support drug adherence, reducing treatment failures and hospital re-admissions, which is crucial in value-based healthcare systems. Innovations help expand generics beyond simple copycat models, attracting more interest from prescribers and consumers. As the competition is growing, companies are investing in developing superior generic versions, enhancing their appeal and performance while maintaining cost-effectiveness.

Broadening of public and private health insurance coverage

The expansion of public and private health insurance coverage is a key driver of the market as insurers often prioritize cost containment without compromising patient care. Generic drugs offer a financially viable solution for large-scale drug reimbursements, making them a preferred choice in insurance formularies. With broader coverage, more individuals are gaining access to essential medications, and insurers are able to negotiate better pricing on generics through volume-based contracts. In addition, health insurance programs frequently include incentives or mandates to dispense generic versions when available, promoting their widespread use. As insurance penetration is growing in both developed and developing regions, the demand for affordable generic drugs is rising. This trend is supporting consistent growth in manufacturing and distribution of generics, aiding healthcare systems in managing budgets while ensuring patients receive necessary medications through covered plans.

GENERIC DRUGS MARKET SEGMENTATION:

Breakup by Therapy Area:

Central Nervous System
Cardiovascular
Dermatology
Genitourinary/Hormonal
Respiratory
Rheumatology
Diabetes
Oncology
Others

Central Nervous System accounts for the majority of the market share

The central nervous system (CNS) segment holds a significant portion of the generic drugs market, reflecting the high burden of neurological disorders globally. Generic drugs play a crucial role in managing conditions like epilepsy, depression, and anxiety, which require long-term medication. As patents for branded CNS drugs expire, generic versions become increasingly available, offering more affordable options for patients and healthcare systems. This accessibility is essential for ongoing patient care, particularly in lower-income regions where cost can be a significant barrier to treatment. Additionally, the growth in the CNS generics market is further supported by continued research and development efforts, enhancing drug efficacy and patient compliance.

Breakup by Drug Delivery:

Oral
Injectables
Dermal/Topical
Inhalers

Oral holds the largest share of the industry

The oral segment dominates the generic drugs industry due to its widespread preference for drug administration. Oral medications are favored for their convenience, safety, and ease of use, which significantly enhances patient compliance, especially in chronic conditions that require prolonged therapy. This segment's predominance is bolstered by continuous innovations and generic launches that make treatments more accessible and cost-effective. The ability to self-administer oral generics also reduces the need for hospital visits, which is particularly advantageous in reducing healthcare costs and improving the quality of life for patients with ongoing medical needs. As healthcare systems globally push for more cost-effective treatment options, the demand for oral generic drugs continues to grow, maintaining their significant share in the generic drugs market revenue.

Breakup by Distribution Channel:

Retail Pharmacies
Hospital Pharmacies

Retail Pharmacies represents the leading market segment

Retail pharmacies constitute the largest distribution channel in the generic drugs market, driven by their accessibility and convenience for patients. These pharmacies are pivotal in delivering cost-effective generic medications directly to consumers, facilitating immediate access to essential drugs. The widespread presence of retail pharmacies ensures that generic drugs are readily available across various regions, enhancing patient adherence to prescribed therapies. Additionally, retail pharmacies often benefit from strong customer relationships and trust, encouraging the use of generics. With the increasing emphasis on reducing healthcare costs, retail pharmacies continue to play a critical role in the distribution and adoption of generic drugs, reinforcing their leading position in the market.

Breakup by Country:

United States
China
Brazil
Germany
France
India
United Kingdom
Japan
Canada
Italy
Others

United States leads the market, accounting for the largest generic drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include which include the United States, China, Brazil, Germany, France, India, the United Kingdom, Japan, Canada, Italy, and others. According to the report, United States represents the largest regional market, accounting for the majority of generic drugs market value.

The United States holds a dominant position in the global generic drugs market, accounting for the largest market share. This leadership is driven by a robust pharmaceutical infrastructure, high healthcare spending, and a strong emphasis on cost-effective treatment options. The U.S. market is supported by favorable government policies, such as the Generic Drug User Fee Amendments (GDUFA), which aim to speed up the approval process for generic drugs. According to the Association for Accessible Medicines (AAM), the U.S. health care system saved a record $338 billion in 2020 thanks to the use of FDA-approved generic and biosimilar drugs. Generic drugs accounted for 90% of prescriptions but only 18% of prescription drug spending. Biosimilar drugs, while occupying less than 30% of the market, saved $7.9 billion in 2020, indicating their growing impact on cost savings. Additionally, the vast network of retail pharmacies across the country ensures widespread availability and accessibility of generic medications to the American population. The U.S.'s significant role in pharmaceutical innovation and a mature healthcare system further consolidate its leading status in the generic drugs market.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the generic drugs industry include Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited and Aspen Pharmacare Holdings Limited, etc. ()
The generic drugs market is highly competitive, characterized by numerous players and a focus on cost efficiency and market penetration. Leading companies like Teva, Mylan, and Sandoz dominate due to their extensive product portfolios and global reach. These companies leverage robust manufacturing capabilities and strategic partnerships to maintain their market positions. The competition is further intensified by new entrants and local manufacturers, especially in high-growth regions like Asia-Pacific. Price wars are common, as companies aim to undercut competitors, often leading to significant price reductions. Regulatory support for generics and patent expiries of blockbuster drugs also fuel the competitive dynamics, pushing companies to innovate and expand their generic drug offerings.

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Generic Drugs Industry

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Country
5.5 Market Breakup by Therapy Area
5.6 Market Breakup by Drug Delivery
5.7 Market Breakup by Distribution Channel
5.8 Market Forecast
5.9 SWOT Analysis
- 5.9.1 Overview
- 5.9.2 Strengths
- 5.9.3 Weaknesses
- 5.9.4 Opportunities
- 5.9.5 Threats
5.10 Value Chain Analysis
- 5.10.1 Research and Development
- 5.10.2 Manufacturing
- 5.10.3 Marketing and Distribution
5.11 Porter's Five Forces Analysis
- 5.11.1 Overview
- 5.11.2 Bargaining Power of Buyers
- 5.11.3 Bargaining Power of Suppliers
- 5.11.4 Degree of Competition
- 5.11.5 Threat of New Entrants
- 5.11.6 Threat of Substitutes
5.12 Regulations in the Generic Industry
5.13 Key Market Drivers and Success Factors

6 Performance of Key Countries

6.1 United States
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 China
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Brazil
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Germany
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 France
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 India
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 United Kingdom
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
6.8 Japan
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
6.9 Canada
- 6.9.1 Market Trends
- 6.9.2 Market Forecast
6.10 Italy
- 6.10.1 Market Trends
- 6.10.2 Market Forecast
6.11 Others
- 6.11.1 Market Trends
- 6.11.2 Market Forecast

7 Market Breakup by Therapy Area

7.1 Central Nervous System
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Cardiovascular
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Dermatology
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Genitourinary/Hormonal
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Respiratory
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Rheumatology
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
7.7 Diabetes
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
7.8 Oncology
- 7.8.1 Market Trends
- 7.8.2 Market Forecast
7.9 Others
- 7.9.1 Market Trends
- 7.9.2 Market Forecast

8 Market Breakup by Drug Delivery

8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Injectables
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Dermal/Topical
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Inhalers
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Retail Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Hospital Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast

10 Competitive Landscape

10.1 Market Structure
10.2 Market Breakup by Key Players
10.3 Key Player Profiles
- 10.3.1 Teva Pharmaceuticals Industries Ltd.
- 10.3.2 Mylan N.V.
- 10.3.3 Novartis AG
- 10.3.4 Pfizer Inc.
- 10.3.5 Sun Pharmaceutical Industries Ltd.
- 10.3.6 Fresenius SE & Co.
- 10.3.7 Lupin Limited
- 10.3.8 Endo Pharmaceuticals Inc.
- 10.3.9 Aurobindo Pharma Limited
- 10.3.10 Aspen Pharmacare Holdings Limited